245 related articles for article (PubMed ID: 30847840)
1. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
5. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y; Yadugiri S; Yeboa DN; Ferguson SD; Forsyth PA; Oliva ICG
Curr Oncol Rep; 2022 Jan; 24(1):43-54. PubMed ID: 35059999
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
[TBL] [Abstract][Full Text] [Related]
7. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.
Glitza IC; Rohlfs M; Guha-Thakurta N; Bassett RL; Bernatchez C; Diab A; Woodman SE; Yee C; Amaria RN; Patel SP; Tawbi H; Wong M; Hwu WJ; Hwu P; Heimberger A; McCutcheon IE; Papadopoulos N; Davies MA
ESMO Open; 2018; 3(1):e000283. PubMed ID: 29387478
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.
Mandel JJ; Yust-Katz S; Cachia D; Wu J; Liu D; de Groot JF; Yung AW; Gilbert MR
J Neurooncol; 2014 Dec; 120(3):597-605. PubMed ID: 25168214
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients.
Rozendorn N; Shutan I; Feinmesser G; Grynberg S; Hodadov H; Alon E; Asher N
Laryngoscope; 2024 Jun; 134(6):2762-2770. PubMed ID: 38230960
[TBL] [Abstract][Full Text] [Related]
11. Identification of risk factors associated with leptomeningeal disease after resection of brain metastases.
Morshed RA; Saggi S; Cummins DD; Molinaro AM; Young JS; Viner JA; Villanueva-Meyer JE; Goldschmidt E; Boreta L; Braunstein SE; Chang EF; McDermott MW; Berger MS; Theodosopoulos PV; Hervey-Jumper SL; Aghi MK; Daras M
J Neurosurg; 2023 Aug; 139(2):402-413. PubMed ID: 36640095
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
Barbour AB; Blouw B; Taylor LP; Graber JJ; McGranahan T; Blau M; Halasz LM; Lo SS; Tseng YD; Venur V; Yang JT
J Neurooncol; 2024 May; 167(3):509-514. PubMed ID: 38441840
[TBL] [Abstract][Full Text] [Related]
13. Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review.
Wallace G; Kundalia R; Cao B; Kim Y; Smalley I; Forsyth P; Soyano A; Pina Y
Res Sq; 2023 Jun; ():. PubMed ID: 37333166
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination.
Mazloom A; Hodges JC; Teh BS; Chintagumpala M; Paulino AC
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):350-4. PubMed ID: 22401918
[TBL] [Abstract][Full Text] [Related]
15. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
17. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.
Yust-Katz S; Garciarena P; Liu D; Yuan Y; Ibrahim N; Yerushalmi R; Penas-Prado M; Groves MD
J Neurooncol; 2013 Sep; 114(2):229-35. PubMed ID: 23756727
[TBL] [Abstract][Full Text] [Related]
19. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.
Raizer JJ; Hwu WJ; Panageas KS; Wilton A; Baldwin DE; Bailey E; von Althann C; Lamb LA; Alvarado G; Bilsky MH; Gutin PH
Neuro Oncol; 2008 Apr; 10(2):199-207. PubMed ID: 18287337
[TBL] [Abstract][Full Text] [Related]
20. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.
Siomin VE; Vogelbaum MA; Kanner AA; Lee SY; Suh JH; Barnett GH
J Neurooncol; 2004; 67(1-2):115-21. PubMed ID: 15072456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
